S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
NASDAQ:RCKT

Rocket Pharmaceuticals Stock Forecast, Price & News

$23.67
-1.46 (-5.81%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$23.35
$25.12
50-Day Range
$25.13
$36.02
52-Week Range
$23.35
$67.48
Volume
269,235 shs
Average Volume
431,095 shs
Market Capitalization
$1.53 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.66
30 days | 90 days | 365 days | Advanced Chart
Receive RCKT News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Rocket Pharmaceuticals logo

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in New York, NY.

Headlines

Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 12-Month Low at $24.47
November 24, 2021 |  americanbankingnews.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 1-Year Low at $26.62
November 15, 2021 |  americanbankingnews.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 5.6%
November 12, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RCKT
Employees
101
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$7.54 per share

Profitability

Net Income
$-139.70 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
40,921,000
Market Cap
$1.53 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/03/2021
Today
11/26/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

MarketRank

Overall MarketRank

2.34 out of 5 stars

Medical Sector

230th out of 1,392 stocks

Pharmaceutical Preparations Industry

101st out of 670 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions

Is Rocket Pharmaceuticals a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Rocket Pharmaceuticals stock.
View analyst ratings for Rocket Pharmaceuticals
or view top-rated stocks.

How has Rocket Pharmaceuticals' stock price been impacted by Coronavirus?

Rocket Pharmaceuticals' stock was trading at $15.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RCKT shares have increased by 48.0% and is now trading at $23.67.
View which stocks have been most impacted by COVID-19
.

When is Rocket Pharmaceuticals' next earnings date?

Rocket Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Rocket Pharmaceuticals
.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its earnings results on Wednesday, November, 3rd. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by $0.19. During the same quarter in the previous year, the business earned ($0.53) earnings per share.
View Rocket Pharmaceuticals' earnings history
.

What price target have analysts set for RCKT?

10 Wall Street analysts have issued 1 year target prices for Rocket Pharmaceuticals' shares. Their forecasts range from $56.00 to $100.00. On average, they anticipate Rocket Pharmaceuticals' share price to reach $73.14 in the next year. This suggests a possible upside of 209.0% from the stock's current price.
View analysts' price targets for Rocket Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Rocket Pharmaceuticals' key executives?

Rocket Pharmaceuticals' management team includes the following people:
  • Gaurav Shah, President, Chief Executive Officer & Director
  • Kinnari Patel, Chief Operating Officer & EVP-Development
  • Carlos Garcia-Parada, Chief Financial Officer
  • Jonathan David Schwartz, Chief Medical Officer & SVP-Clinical Development
  • Isabel Carmona, Chief Human Resources Officer & Senior VP

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include RTW Investments LP (24.52%), Wellington Management Group LLP (5.19%), BlackRock Inc. (5.00%), Maverick Capital Ltd. (2.58%), Franklin Resources Inc. (2.09%) and Janus Henderson Group PLC (1.91%). Company insiders that own Rocket Pharmaceuticals stock include Gotham Makker, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends for Rocket Pharmaceuticals
.

Which institutional investors are selling Rocket Pharmaceuticals stock?

RCKT stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Lord Abbett & CO. LLC, Invesco Ltd., Dimensional Fund Advisors LP, BNP Paribas Arbitrage SA, Franklin Resources Inc., Great Point Partners LLC, and Affinity Asset Advisors LLC. Company insiders that have sold Rocket Pharmaceuticals company stock in the last year include Gotham Makker, Kinnari Patel, and Rtw Investments, Lp.
View insider buying and selling activity for Rocket Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Rocket Pharmaceuticals stock?

RCKT stock was bought by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., RTW Investments LP, Nordea Investment Management AB, Goldman Sachs Group Inc., Barclays PLC, Renaissance Technologies LLC, Alliancebernstein L.P., and UBS Group AG. Company insiders that have bought Rocket Pharmaceuticals stock in the last two years include Kinnari Patel, and Rtw Investments, Lp.
View insider buying and selling activity for Rocket Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $23.67.

How much money does Rocket Pharmaceuticals make?

Rocket Pharmaceuticals has a market capitalization of $1.53 billion. The biotechnology company earns $-139.70 million in net income (profit) each year or ($3.07) on an earnings per share basis.

How many employees does Rocket Pharmaceuticals have?

Rocket Pharmaceuticals employs 101 workers across the globe.

What is Rocket Pharmaceuticals' official website?

The official website for Rocket Pharmaceuticals is www.rocketpharma.com.

Where are Rocket Pharmaceuticals' headquarters?

Rocket Pharmaceuticals is headquartered at 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company can be reached via phone at (646) 440-9100, via email at [email protected], or via fax at 646-224-9585.


This page was last updated on 11/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.